Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial

Head and Neck Cancer

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Lancet Oncol

Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS, HNCIG

doi: 10.1016/S1470-2045(24)00068-8

Head and Neck Cancer

Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors

Eur J Cancer

Salvestrini V, Bonaparte I, Becherini C, Desideri I, Caini S, Palomba A, Bertini N, Mattioli C, Simontacchi G, Francolini G, Greto D, Loi M, Di Cataldo V, Livi L, Bonomo P

doi: 10.1016/j.ejca.2025.115260

Head and Neck Cancer

Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial

CA Cancer J Clin

Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Y, Li JB, Liu N, Xie FY, Guo R, Sun Y, Ma J

doi: 10.3322/caac.21881

Head and Neck Cancer

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

J Clin Oncol

Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr

doi: 10.1200/JCO.23.02625

Head and Neck Cancer

A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies

Cancer Treat Rev

Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O'Leary B, Braña I, Harrington KJ

doi: 10.1016/j.ctrv.2024.102772

Head and Neck Cancer

Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives

Cancer Treat Rev

Jiménez-Labaig P, Rullan A, Braña I, Hernando-Calvo A, Moreno V, Doger B, Bitar G, Ap Dafydd D, Melcher A, Harrington KJ

doi: 10.1016/j.ctrv.2024.102746

Head and Neck Cancer

Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis

Clin Cancer Res

Saba NF, Chaudhary R, Kirtane K, Marra A, Ekpenyong A, McCook-Veal A, Schmitt NC, Gross JH, Patel MR, Remick J, Bates JE, McDonald MW, Rudra SF, Stokes WA, Biernacki M, Song X, Slebos RJC, Liu Y, Steuer CE, Shin DM, Teng Y, Chung CH

doi: 10.1158/1078-0432.CCR-24-1202

Genitourinary Cancer

IMPACT OF 3D-PRINTED MODELS FOR SURGICAL PLANNING IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS. A RANDOMISED MULTICENTER CLINICAL TRIAL

J Urol

Rivero-Belenchón I, Congregado Ruíz CB, Gómez Ciriza G, Gómez Dos Santos V, Burgos Revilla FJ, Medina López RA

doi: 10.1097/JU.0000000000004425

Lung, Respiratory and Thoracic Cancer

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial

J Clin Oncol

Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD, Ottosson W, Brink C, Hoffmann L

doi: 10.1200/JCO-24-01386

Related content

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors

Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies

Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives

Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis

IMPACT OF 3D-PRINTED MODELS FOR SURGICAL PLANNING IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS. A RANDOMISED MULTICENTER CLINICAL TRIAL

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial